Bharat Biotech says Covaxin shows 78pc efficacy against mild to severe COVID-19
Bharat Biotech said the second interim data of the Covaxin Phase III study showed chances of hospitalisation was reduced by 100 percent after taking the jab.
Bharat Biotech on Wednesday said its coronavirus vaccine Covaxin has shown the efficacy of 78 percent against mild, moderate, and severe cases of COVID-19 as per Phase III interim analysis results.
The vaccine maker noted that the second interim data of the Phase III study also showed that chances of hospitalisation due to the infectious disease were reduced by 100 percent after taking the Covaxin jab.
Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 percent against mild, moderate, and severe COVID-19 disease, Bharat Biotech said in a statement.
The efficacy against asymptomatic COVID-19 infection was 70 percent, suggesting decreased transmission in Covaxin recipients, it added.
"Efficacy against SARS-CoV-2 has been established. Covaxin has demonstrated an excellent safety record in human clinical trials and usage under emergency use. Covaxin is now a global innovator vaccine derived from R&D in India," Bharat Biotech Chairman and Managing Director Krishna Ella said.
The efficacy data against severe COVID-19 and asymptomatic infections is highly significant as this helps reduce hospitalisations and disease transmission, respectively, he added.
The protocols for manufacturing, testing, and release of inactivated vaccines have been tried, tested, and validated across several of the company's vaccines. These also meet the requirements of WHO, as well as Indian and other regulatory authorities, Ella said.
"These protocols have delivered consistent results over a 15-year period with over 300 million doses supplied globally with excellent safety and performance record," he added.
Bharat Biotech said safety and efficacy results from the final analysis will be available in June. The final report will be submitted to a peer-reviewed publication.
The Phase III study for Covaxin enrolled 25,800 participants between 18-98 years of age, including 10 percent over the age of 60, with analysis conducted 14 days post the second dose.
Covaxin has been developed with seed strains received from the National Institute of Virology. The Phase III clinical trial was co-funded by the Indian Council of Medical Research (ICMR), making it a public-private partnership towards public health.
"The tireless efforts of our scientists at ICMR and Bharat Biotech have resulted in a truly effective international vaccine of the highest standards and efficacy. I am also happy to note that Covaxin works well against most variants of SARS-CoV-2. These findings together consolidate the position of our indigenous vaccine in the global vaccine landscape," Balram Bhargava, Secretary, Department of Health Research, and Director-General of ICMR, said.
Edited by Suman Singh